{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:04Z","timestamp":1785542404755,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0799-8","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T09:47:44Z","timestamp":1514540864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-4733","authenticated-orcid":false,"given":"Akira","family":"Yamagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Imakiire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"799_CR1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comezo RL, Skinner M. The systemic amyloidosis. N Engl J Med. 1997;337:898\u2013909.","journal-title":"N Engl J Med"},{"key":"799_CR2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.24735","volume":"61","author":"L Obici","year":"2009","unstructured":"Obici L, Raimondi S, Lavetelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic disease: a critical overview. Arthritis Rheum. 2009;61:1435\u201340.","journal-title":"Arthritis Rheum"},{"key":"799_CR3","first-page":"850","volume":"29","author":"T Nakamura","year":"2011","unstructured":"Nakamura T. Amyloid a amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment. Clin Exp Rheumatol. 2011;29:850\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"799_CR4","first-page":"823093","volume":"2014","author":"M Matsui","year":"2014","unstructured":"Matsui M, Okayama S, Tsushima H, Samejima K, Kanki T, Hasegawa A, et al. Therapeutic benefits of tocilizumab vary in different organs of a patient with AA amyloidosis. Case Rep Nephrol. 2014;2014:823093.","journal-title":"Case Rep Nephrol"},{"key":"799_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/14397595.2013.844294","volume":"24","author":"I Miyagawa","year":"2014","unstructured":"Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, et al. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatology. 2014;24:405\u20139.","journal-title":"Mod Rheumatology"},{"key":"799_CR6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s10067-010-1422-6","volume":"29","author":"D Inoue","year":"2010","unstructured":"Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29:1195\u20137.","journal-title":"Clin Rheumatol"},{"key":"799_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","volume":"31","author":"R Topaloglu","year":"2016","unstructured":"Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31:633\u201340.","journal-title":"Pediatr Nephrol"},{"key":"799_CR8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000183466","volume":"40","author":"G Karsenty","year":"1985","unstructured":"Karsenty G, Ulmann A, Droz D, Carnot F, Grunfeld JP. Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal. Nephron. 1985;40:232\u20134.","journal-title":"Nephron"},{"key":"799_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0046-8177(83)80016-1","volume":"14","author":"PR Vanatta","year":"1983","unstructured":"Vanatta PR, Silva FG, Taylor WE, Costa JC. Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature. Hum Pathol. 1983;14:195\u2013201.","journal-title":"Hum Pathol"},{"key":"799_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13730-013-0088-8","volume":"3","author":"A Babu","year":"2014","unstructured":"Babu A, Lachmann H, Pickett T, Boddana P, Ludeman L. Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Rep. 2014;3:68\u201374.","journal-title":"CEN Case Rep"},{"key":"799_CR11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1046\/j.1523-1755.2000.00334.x","volume":"58","author":"C Bazzi","year":"2000","unstructured":"Bazzi C, Petrini C, Rizza V, Arrigo G, D\u2019Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int. 2000;58:1732\u201341.","journal-title":"Kidney Int"},{"key":"799_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2141.1997.303194.x","volume":"99","author":"JD Gillmore","year":"1997","unstructured":"Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol. 1997;99:245\u201356.","journal-title":"Br J Haematol"},{"key":"799_CR13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000348803","volume":"37","author":"T Shimo","year":"2013","unstructured":"Shimo T, Adachi Y, Yamanouchi S, Tsuji S, Kimata T, Umezawa K, et al. A novel nuclear factor \u03baB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice. Am J Nephrol. 2013;37:302\u20139.","journal-title":"Am J Nephrol"},{"issue":"Suppl. 94","key":"799_CR14","first-page":"S46","volume":"33","author":"T Lane","year":"2015","unstructured":"Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(Suppl. 94):S46\u201353.","journal-title":"Clin Exp Rheumatol"},{"key":"799_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2013.854048","volume":"24","author":"Y Okuda","year":"2014","unstructured":"Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24:137\u201343.","journal-title":"Mod Rheumatol"},{"key":"799_CR16","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","volume":"54","author":"Y Okuda","year":"2006","unstructured":"Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, Tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:2997\u20133000.","journal-title":"Arthritis Rheum"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0799-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T09:47:49Z","timestamp":1514540869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0799-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0799-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"377"}}